ABSTRACT
Iron deficiency is one of the heart failure comorbidities. This study aims to evaluate and conclude the cost-effectiveness of ferric carboxymaltose in heart failure patients with iron deficiency. This was a systematic review of all articles collected from PubMed, Scopus, Web of Science, EBSCO, ProQuest, Science Direct, and Global Health Databases, published from 2012 to 2022. Seven studies from 679 articles were included. One article used the Markov model study design, five articles used a model-based study, and one article used a cost-utility approach. South Korea has the highest ICERs at $18.254/QALY. Ferric carboxymaltose is cost-effective for heart failure with iron deficiency, with an average ICER value of $7,814/QALY and a median value of $6,678/QALY.
